Pipeline Information
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-3245 (BRAF inhibitor)
Advanced solid tumors with B-RAF mutations
Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)
Advanced solid tumors
Pamiparib (PARP 1/2 inhibitor)
2L/3L maintenance platinum-sensitive OC
1L maintenance platinum-sensitive GC
BRCA+ and HER2– BC
Advanced OC and TNBC
Pamiparib + Temozolomide
Advanced solid tumors
Tislelizumab (anti-PD-1)
2L advanced ESCC
1L HCC
2L/3L NSCLC
Previously treated unresectable HCC
Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab + BGB-A425 (anti-TIM-3)
Advanced solid tumors
Tislelizumab + BGB-A445 (anti-OX40)
Advanced solid tumors
Tislelizumab + Ociperlimab (anti-TIGIT)
1L PD-L1 high advanced NSCLC
2L PD-L1+ advanced ESCC
2L+ cervical cancer
Advanced solid tumors
Tislelizumab + Ociperlimab + BAT1706
1L HCC
Tislelizumab + Ociperlimab + Chemotherapy
1L NSCLC
Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy
Previously untreated, stage III unresectable NSCLC
Previously untreated LS-SCLC
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)
Advanced solid tumors
Tislelizumab + BGB-15025 (HPK1 inhibitor)
Advanced solid tumors
Tislelizumab + Chemoradiotherapy
Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy
Resectable ESCC
Tislelizumab + Chemotherapy
1L advanced ESCC
1L GC/GEJC
Resectable stage II or IIIA NSCLC
1L advanced nasopharyngeal cancer
1L squamous NSCLC
1L non-squamous NSCLC
1L advanced UBC
1L ES-SCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy
1L/2L GC/GEJC
Tislelizumab + Fruquintinib (VEGFR inhibitor)
Advanced GC/GEJC, CRC, and NSCLC
Advanced triple negative BC
Tislelizumab + Lenvatinib
1L HCC
Advanced solid tumors
Tislelizumab + Sitravatinib (multikinase inhibitor)
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced GC/GEJC/HCC
Advanced solid tumors
Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)
Advanced solid tumors
Zanidatamab (anti-HER2 bispecific antibody)
2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab
1L HER2+ BC and 1L HER2+ GC/GEJC
Australia
Australia, China
Australia, New Zealand
Australia, New Zealand, US
Australia, S.Korea, US
Australia, US
China
China, S. Korea
China, Thailand
S. Korea, US
United States
Worldwide
BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab (anti-PD-1)
R/R cHL
R/R cHL
BGB-10188 +/- Tislelizumab
B-cell malignancies
BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK inhibitor)
B-cell lymphoid malignancies
BGB-11417 (Bcl-2 inhibitor) monotherapy
Mature B-cell malignancies
Zandelisib (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*
CLL/SLL and B-cell NHL
Zanubrutinib
R/R CLL/SLL
1L and R/R WM
R/R MZL
Previously treated B-cell lymphoid malignancies
B-cell lymphoid malignancies
Zanubrutinib + Lenalidomide +/- Rituximab
R/R DLBCL
Zanubrutinib + Obinutuzumab
R/R FL
Zanubrutinib + Rituximab
1L MCL
Zanubrutinib +/- Venetoclax†
1L CLL/SLL
Australia
China
Japan
Switzerland, US
United States
Worldwide
* In collaboration with MEI Pharma
† This combination is being studied in the third cohort of NCT03336333
B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
